Statement of Deviation or variation for the quarter ended June 30, 2026 on the use of proceeds of Funds raised through Qualified Institutional Placement.

OrchidPharm~W August 14, 2026 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Subject: Statement of deviation or variation for the quarter ended June 30, 2026 on the use of proceeds of Funds raised through Qualified Institutional Placement (QIP) Dear Sir/Madam, With reference to aforesaid subject and pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, Statement of Deviation for the quarter ended June 30, 2026, duly reviewed by the Audit Committee of the Company is attached herewith. You are requested to kindly take the same on record +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor. Tower 1, DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. OrchidPharm~W -- A Dhanuka Group Company ----------------------------------- STATEMENT OF DEVIATION OR VARIATION UNDER REGULATION 32 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REOUIREMENTS) REGULATIONS, 2015 FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, OUALIFIED INSTITUTIONS PLACEMENT ETC. Name of listed entity Orchid Pharma Limited Mode of Fund Raising Qualified Institutions Placement Date of Raising Funds June 27, 2023 Amou nt Ra ised RsAOO Crores Report filed for Quarter ended June 30, 2026 Monitoring Agency Applicable Monitoring Agency Name, if applicable Care Ratings Limited Is there a Deviation I Variation in use Yes of funds raised If yes, whether the same is pursuant Yes to change in terms of a contract or objects, which was approved by the shareholders If Yes, Date of shareholder Approval September 20, 2025 Explanation for the Deviation I In view of changes in the business Variation environment and to meet current strategic requirements, the Company has modified the allocation of the QIP Proceeds. The commencement of "new block at API Facility of the Company in Alathur" project has been postponed to a later stage. Therefore, QIP Proceeds allotted to API Facility in Alathur has been reallocated with the approval of shareholders at the AGM held on September 30, 2025, to mitigate such additional financial burden, improve profit and ensure the best possible utilization of the QIP proceeds in the overall interest of the Company and its shareholders. Comments of the Audit Committee As per attached Annexure after review Comments of the auditors, if any NA Objects for which funds have been l. Investment in our wholly owned raised and where there has been a Subsidiary, Orchid Bio-Pharma deviation, in the following table Limited, ("OBPL") for setting up a new manufacturing facility in Jammu ("Jammu Manufacturing Facility"); 2. Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by our Company; 3. Funding capital expenditure reqUirements for settinq up a new corporate@orc~~~ +91-44-27444471/72/73 • orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: ~" Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151,159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. OrchidPharm~W -- A Dhanuka Group Company ----------------------------------- block at API Facility of the Company in Alathur, Tamil Nadu; and 4. General corporate purposes. S Original Object Modi Origin Modifi Fun Amount of Rem r. fied al ed ds Deviation/ arks N Obje Allocat alloca Utili Variation if o. ct, if ion tion, sed for the any any (Rs. in if any (Rs. quarter (Rs. Lakhs) (Rs. in according in in Lak to Lakh Lakhs hs) applicable s) ) object (Rs. in Lakhs) 1 Investment in OBPL No 9000 13500 9762 0 for setting up Jammu Manufacturing Facility 2 Repaymentjprepayme No 14100 19546 1954 0 nt, in full or in part, of 6 certain outstanding borrowings availed by our Company 3 Funding capital No 9982 36 36 0 expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu 4 General corporate No 6098* 6372 6372 0 purposes ("GCP") * As per the QIP offer document the amount allocated for GCP was Rs.6098 Lakhs which was on the basis of proposed net proceeds after issue expenses, being Rs.39180 Lakhs. However, net Proceeds transferred to Monitoring Account was Rs.39454 Lakhs as against the proposed Net Proceeds of Rs.39180 Lakhs, therefore the GCP was revised to Rs.274 lakhs has been included in the GCP and K& pi yya *" O,,>.:y CO any Secretary &c-ompliance Officer ----_._--------------- +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. OrchidPharm~W -- A Dhanuka Group Company ------------------------------------- Annexure s. Para Particulars/ Item Comments of Comments of Audit No No. of Head Monitoring Agency Committee Report 1 3 Whether all utilization is The company revised the The comments of as per the disclosure in allocation of QIP Monitoring Agency are the Offer Document? proceeds among the self-explanatory objects specified in the offer document, pursuant to shareholders' approval obtained through the AGM resolution dated September 20, 2025. Accordingly, the utilisation of funds is now being undertaken in line with the revised allocation schedule. 2 3 Whether shareholder Change in allocation of The comments of approval has been funds towards the Monitoring Agency are obtained in case of objects of the issue was self-explanatory material deviations from approved by expenditures disclosed in shareholders vide AGM the Offer Document? resolution dated September 20, 2025. 3 3 Whether the means of The company revised the The comments of finance for the disclosed allocation of QIP Monitoring Agency are objects of the issue have proceeds among the self-explanatory changed? objects specified in the offer document, pursuant to shareholders' approval obtained through the AGM resolution dated September 20, 2025. Accordingly, the utilisation of funds is now being undertaken in line with the revised allocation schedule 4 3 Whether all No specific list of The comments of Govern ment/statutory statutory/ Govt Monitoring Agency are approvals related to the Approvals was self-explanatory object(s) have been mentioned in the offer obtained? document for the purpose of monitoring. As per the AGM dated Sep 20, 2025, no further investment is expected towards Alathur project from QIP proceeds. 5 3 Whether all The company has spent The comments of arrangements pertaining I R~~. 7 crores towards Monitoring Agency are to technical !1Q€ !J..CJj&iX now-how. self-explanatory ::f.t \,)' +91-44-27444471/72/73 • corporate@orchidphar~~ om • ru-thidpharma.com • CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited {\-~ ~ 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151,159-164, SIDCO Indu ial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. OrchidPharm~W -- A Dhanuka Group Company ------------------------------------- assista nce/c olla boration are in operation? 6 3 Are there any There is significant delay The Land acquisition task favorable/unfavorable in the implementation of has been given to Land events affecting the the manufac [Showing first 8,000 characters — download PDF for full document]